1. Pharmaceutical composition for the prevention or treatment of cancer, containing two or more epigenetic modifiers. The pharmaceutical composition according to claim 1, characterized in that said two or more epigenetic modifiers are histone deacetylase inhibitors or demethylating agents. The pharmaceutical composition of claim 1, wherein said two or more epigenetic modifiers are selected from the group consisting of sodium phenyl butyrate (FBN), lipoic acid (LC), quercetin, valproic acid, hydralazine, bactrim, green tea extract, epigallocatechin gallate, curcumin, sulforaphane, and allicin / diallyl disulfide. 4. The pharmaceutical composition of claim 3, comprising sodium phenyl butyrate (FBN) and quercetin. The pharmaceutical composition according to claim 4, characterized in that the pharmaceutical composition is presented in the form of a dosage form containing from about 1.0 g to about 10.0 g of sodium phenylbutyrate (FBN) and from about 0.5 g to about 1.5 g of quercetin. 6. The pharmaceutical composition according to claim 3, containing quercetin and lipoic acid (LK). 7. The pharmaceutical composition of claim 6, wherein said pharmaceutical composition is presented in a dosage form containing from about 0.5 g to about 1.5 g of quercetin and from about 200 mg to about 1000 mg of lipoic acid (LA). . The pharmaceutical composition of claim 3, comprising lipoic acid (LK) and sodium phenylbutyrate (FBN). The pharmaceutical composition of claim 8, wherein said pharmaceutical composition is presented in a dosage form containing from about 200 mg to about 1000 mg of lipoic acid (LA) and from about 1.0 g to about 10.0 g of phenylbutyrate per1. Фармацевтический состав для профилактики или лечения рака, содержащий два или более эпигенетических модификаторов.2. Фармацевтический состав по п. 1, отличающийся тем, что указанные два или более эпигенетических модификаторов представляют собой ингибиторы деацетилаз гистонов или деметилирующие агенты.3. Фармацевтический состав
